Biohaven Ltd. (BHVN) Stock Price
BHVNStock
$15.41−0.71%52W
Market Cap$2.33B
P/E—
PEG Ratio—
Div yield—
Beta3.10
BHVN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)18.00%
Price vs S&P 500 (4W)13.72%
VGM Score75.67
BHVN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.61 | -$0.78 | -27.61%(-$0.17) | |
| Q1 2026 | -$0.76 | -$0.69 | +9.68%(+$0.07) | |
| Q4 2025 | -$0.96 | -$0.90 | +5.77%(+$0.06) | |
| Q3 2025 | -$1.93 | -$1.64 | +14.94%(+$0.29) | |
| Q2 2025 | -$1.57 | -$1.63 | -3.96%(-$0.06) |
BHVN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.04
4.04
4.00
4.04
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BHVNBiohaven Ltd. | — | — | B | $15.41 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Biohaven Ltd.
Biohaven is a clinical-stage biopharmaceutical company developing treatments across immunology, neuroscience, and oncology. Its pipeline targets neuromuscular diseases, metabolic disorders, obsessive-compulsive disorder, and cancer, utilizing multiple therapeutic modalities including glutamate modulators, myostatin inhibitors, ion channel modulators, and antibody-drug conjugates. The company has multiple product candidates spanning these therapeutic areas at various development stages.